Breaking Finance News

ValuEngine upgraded Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to Sell in a report released today.

Yesterday Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) traded -1.60% lower at $3.90. The company’s 50-day moving average is $1.68 and its 200-day moving average is $2.82. The last closing price is up -34.50% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 2,723,089 shares of the stock traded hands, up from an average trading volume of 579,758

ValuEngine has upgraded Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to Sell in a report released on 6/2/2017.

See Chart Below

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals Inc has a 52 week low of $1.40 and a 52 week high of $4.69 The company’s market cap is currently $0.

General Information About Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.